Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antibiotic
quinolone |
| gptkbp:ATCCode |
J01MB02
|
| gptkbp:CASNumber |
389-08-2
|
| gptkbp:chemicalFormula |
C12H12N2O3
|
| gptkbp:contraindication |
pregnancy
children under 3 months |
| gptkbp:discoveredBy |
1962
|
| gptkbp:eliminationHalfLife |
1–2.5 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:first_marketed_by |
gptkb:Sterling_Drug
|
| https://www.w3.org/2000/01/rdf-schema#label |
nalidixic acid
|
| gptkbp:IUPACName |
1-ethyl-7-methyl-4-oxo-1,8-naphthyridine-3-carboxylic acid
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits DNA gyrase
|
| gptkbp:meltingPoint |
227–230 °C
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:molecularWeight |
250.24 g/mol
|
| gptkbp:origin |
synthesized from naphthyridine
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting headache rash |
| gptkbp:synonym |
Negram
NegGram |
| gptkbp:usedFor |
urinary tract infections
|
| gptkbp:bfsParent |
gptkb:fluoroquinolones
gptkb:DNA_gyrase |
| gptkbp:bfsLayer |
6
|